In Vivo | PK PD Pharmacokinetics | Mechanism of Toxicology | MTD NOAEL | Cancer model
Drik determines the Median Lethal Dose/Maximum Tolerated Dose (MTD) and No Observable Adverse Effect Level (NOAEL) in toxicity studies. PK/PD Pharmacokinetic modeling enable selection of appropriate dose levels. Cancer model available include cell lines of interest, xenograft, orthotopic and PDX studies. Drugs marketed should be safe and be effective to patients. Evaluating mechanism of drug action or drug metabolites resulting in toxicity can be evaluated. Drug discovery includes many studies to define proof of concept. But most important step includes pre-clinical research and clinical trials.
The following in vivo studies are currently offered in rodents/dogs (non-GLP; GLP: collaborators) including PK/TK studies. We make use of our partner sites for GLP studies.